PMID- 19919879
OWN - NLM
STAT- MEDLINE
DCOM- 20100205
LR  - 20161125
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 116
IP  - 2
DP  - 2010 Feb
TI  - Preoperative assessment of HER-2/neu status in breast carcinoma: the role of 
      quantitative real-time PCR on core-biopsy specimens.
PG  - 234-9
LID - 10.1016/j.ygyno.2009.10.067 [doi]
AB  - OBJECTIVES: Knowledge of HER-2/neu status is mandatory to identify breast cancer 
      patients amenable to trastuzumab treatment. We evaluated the diagnostic 
      performance of quantitative real-time polymerase chain reaction (qRT-PCR) in the 
      preoperative determination of HER-2/neu status in breast cancer, using core 
      biopsy material. METHODS: In a prospective series, qRT-PCR was performed on fresh 
      core biopsy specimens taken preoperatively in 87 patients with breast carcinoma. 
      Cases with qRT-PCR ratio > or = 2.0 were considered to have HER-2/neu 
      amplification. The results of RT-PCR analysis were compared with those of the 
      standard immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) 
      methods. Cases with IHC 3+ or with IHC 2+ and FISH showing amplification were 
      considered HER-2/neu positive. All other cases were considered HER-2/neu 
      negative. RESULTS: qRT-PCR showed HER-2/neu amplification in 13 cases (14.9%), 
      while the standard IHC-FISH combined approach identified 17 HER-2/neu-positive 
      cases (19.5%). Overall, there was concordance between methods in 83 of 87 
      patients (95.4%). The Spearman's rho correlation coefficient was 0.851; p<0.001. 
      The diagnostic performance for preoperative diagnosis of HER-2/neu status using 
      RT-PCR on core biopsy specimens as compared to standard approach was as follows: 
      sensitivity 76.5%; specificity 100%; positive predictive value 100%; negative 
      predictive value 94.6%. CONCLUSIONS: Quantitative RT-PCR determination of 
      HER-2/neu status from core biopsy specimens provided results comparable to those 
      given by the standard IHC and FISH methods. The use of qRT-PCR on core biopsy 
      material may represent a very useful and easy tool to enhance early 
      identification of HER-2/neu-positive breast cancer patients who, possibly can 
      benefit from trastuzumab treatment.
CI  - Copyright 2009 Elsevier Inc. All rights reserved.
FAU - Susini, Tommaso
AU  - Susini T
AD  - Department of Gynecology, Perinatology and Human Reproduction, University of 
      Florence, Viale Morgagni, 85 - 50134, Firenze, Italy. tommaso.susini@unifi.it
FAU - Bussani, Cecilia
AU  - Bussani C
FAU - Marini, Giulia
AU  - Marini G
FAU - Nori, Jacopo
AU  - Nori J
FAU - Olivieri, Simone
AU  - Olivieri S
FAU - Molino, Cecilia
AU  - Molino C
FAU - Bianchi, Simonetta
AU  - Bianchi S
FAU - Vezzosi, Vania
AU  - Vezzosi V
FAU - Paglierani, Milena
AU  - Paglierani M
FAU - Giachi, Massimo
AU  - Giachi M
FAU - Borrani, Elena
AU  - Borrani E
FAU - Scarselli, Gianfranco
AU  - Scarselli G
LA  - eng
PT  - Journal Article
DEP - 20091117
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biopsy/methods
MH  - Breast Neoplasms/diagnostic imaging/*enzymology/genetics
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Prospective Studies
MH  - Receptor, ErbB-2/biosynthesis/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction/*methods
MH  - Ultrasonography
EDAT- 2009/11/19 06:00
MHDA- 2010/02/06 06:00
CRDT- 2009/11/19 06:00
PHST- 2009/08/20 00:00 [received]
PHST- 2009/10/16 00:00 [revised]
PHST- 2009/10/19 00:00 [accepted]
PHST- 2009/11/19 06:00 [entrez]
PHST- 2009/11/19 06:00 [pubmed]
PHST- 2010/02/06 06:00 [medline]
AID - S0090-8258(09)00871-3 [pii]
AID - 10.1016/j.ygyno.2009.10.067 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2010 Feb;116(2):234-9. doi: 10.1016/j.ygyno.2009.10.067. Epub 2009 
      Nov 17.